Stryker Corporation announced today a definitive agreement to acquire SafeAir AG, a Swiss medical device company dedicated to the design, development and manufacture of innovative surgical smoke evacuation solutions.
The company’s smoke evacuation products help reduce staff and patient exposure to hazards associated with surgical smoke.
“The acquisition of SafeAir AG is highly complementary to the Surgical business of Stryker’s Instruments division, and strengthens our smoke evacuation portfolio in both the U.S. and Europe,” said Timothy J. Scannell, Group President, MedSurg and Neurotechnology. “This acquisition aligns with Stryker’s focus of providing solutions that result in a higher quality of care and level of safety for both healthcare professionals and patients.”
The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2018.
Source: Street Insider
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
